Akdeniz University, School of Medicine, Department of Pediatric Hematology, Oncology and BMT Unit, Antalya, Turkey.
Turk J Haematol. 2012 Jun;29(2):143-9. doi: 10.5505/tjh.2012.78300. Epub 2012 Jun 15.
The aim of this study was to document hematopoietic stem cell transplantation (HSCT) activity and trends at our treatment center.
Data collected over a 10-year period were retrospectively analyzed, concentrating primarily on types of HSCT, transplant-related mortality (TRM), stem cell sources, indications for HSCT, and causes of death following HSCT.
In total, 222 allogeneic (allo)-HSCT (87.4%) and 32 autologous (auto)-HSCT (12.6%) procedures were performed between 1998 and 2008. Stem cells obtained from unrelated donors were used in 22.6% (50/222) of the allo- HSCTs. Cord blood was the source of hematopoietic stem cells (HSC) in 12.2% of all transplants. The most common indication for allo-HSCT was hemoglobinopathy (43.2%), versus neuroblastoma (53.1%) for auto-HSCT. The TRM rate 1 year post transplantation was 18.3% ± 2.5% for all transplants, but differed according to transplantation type (23.5% ± 7.9% for auto-HSCT and 17.5% ± 2.6% for allo-HSCT). The most common cause of death 1 year post HSCT was infection (35.9%).
The TRM rate in the patients that underwent allo-HSCT was similar to that which has been previously reported; however, the TRM rate in the patients that underwent auto-HSCT was higher than previously reported in developed countries. The selection of these patients to be transplanted must be made attentively.
本研究旨在记录我们治疗中心的造血干细胞移植(HSCT)活动和趋势。
对 10 年来收集的数据进行回顾性分析,主要集中在 HSCT 的类型、移植相关死亡率(TRM)、干细胞来源、HSCT 的适应证以及 HSCT 后死亡的原因。
在 1998 年至 2008 年间,共进行了 222 例异基因(allo)-HSCT(87.4%)和 32 例自体(auto)-HSCT(12.6%)。在 22.6%(50/222)的 allo-HSCT 中使用了来自无关供者的干细胞。在所有移植中,脐带血是造血干细胞(HSC)的来源,占 12.2%。allo-HSCT 的最常见适应证是血红蛋白病(43.2%),而自体 HSCT 的最常见适应证是神经母细胞瘤(53.1%)。移植后 1 年的 TRM 率为所有移植的 18.3%±2.5%,但根据移植类型而有所不同(自体 HSCT 为 23.5%±7.9%,allo-HSCT 为 17.5%±2.6%)。移植后 1 年最常见的死亡原因是感染(35.9%)。
allo-HSCT 患者的 TRM 率与以往报道相似,但自体 HSCT 患者的 TRM 率高于以往报道的发达国家。对这些患者进行移植的选择必须慎重。